Highlights Johnson & Johnson Xetra

Equities

JNJ

US4781601046

Market Closed - Xetra Other stock markets 11:35:56 2024-07-05 EDT			5-day change	1st Jan Change
134.3 ^EUR	-0.72%		-1.93%	-5.21%

07-03	Johnson & Johnson's Rybrevant Approved by Health Canada to Treat Advanced Lung Cancer	MT
07-03	Johnson & Johnson Lung Cancer Drug Gets Health Canada Approval	DJ

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

J&J: promising results in multiple myeloma	07-02	CF
Johnson & Johnson Says Interim Analysis of Blood Cancer Therapy Study Show Promise	07-02	MT
Johnson & Johnson Announces Positive Results from Prespecified Second Interim Analysis of the Phase 3 CARTITUDE-4 Study Evaluating CARVYKTI	07-02	CI
Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial	06-28	MT
J&J Unit's Rybrevant Combo Gets EU Approval	06-28	MT
Johnson & Johnson Announces Positive Results from the Nipocalimab Phase 3 Vivacity-MG3 Study	06-28	CI
Johnson & Johnson's Balversa Gets EU Panel Recommendation for Urothelial Carcinoma	06-28	MT
Dealmakers optimistic on global M&A prospects despite sluggish growth	06-28	RE
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	06-27	RE
US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit	06-24	RE
J&J: 50M pupils helped through 'Sight for Kids' program	06-24	CF
Sector Update: Health Care Stocks Edge Up in Afternoon Trading	06-21	MT
Johnson & Johnson: acquisition of Proteologix completed	06-21	CF
Johnson & Johnson Completes Acquisition of Proteologix	06-21	MT
Johnson & Johnson Completes Acquisition of Proteologix	06-21	MT
Johnson & Johnson Completes Acquisition of Proteologix	06-21	MT
Johnson & Johnson completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.	06-20	CI
Johnson & Johnson Files Application With US FDA Seeking Approval of Tremfya to Treat Crohn's Disease	06-20	MT
Johnson & Johnson Submits Application to U.S. FDA Seek Approval of TREMFYA®? for the Treatment of Moderate to Severe Active Crohn's Disease	06-20	CI
J&J: launches open, secure digital ecosystem	06-20	CF

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm